NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

We spoke to the first author of a new study that could challenge much of what we thought we knew about Alzheimer’s disease.

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...

A simple blood test for insulin resistance could help predict cognitive decline in people with early Alzheimer’s.

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

Up-and-coming Alzheimer’s blood tests may soon be used for people with Down’s syndrome. In a longitudinal biomarker study of adults with three copies of ...

Unfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a growing aging population, Alzheimer’s disease has be ...